Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Improving the persistence of CAR T-cells by understanding senescence
FY 2021-22
Summary
Chimeric antigen receptor (CAR)-T cell therapy has led to improved survival for some patients with relapsed/refractory acute lymphoblastic leukemia (ALL). This therapy involves engineering T cells, a white blood cell, with a new gene, the CAR, so that it can recognize and kill the cancer cells. However, long-term survival remains short for many patients, with poor outcomes associated with a loss of the CAR-T cells. One possible reason for the loss of CAR-T cells is senescence, or aging, of the T cells, resulting in inactivity and cell death. Senescence can occur via telomere-dependent or independent pathways. Telomeres are repeats found on the ends of chromosomes that protect the cellular DNA from damage, and critical shortening of these leads to senescence. Telomere independent senescence is mediated by many different pathways. We propose to examine the pathways of senescence in CAR-T cells and how they differ compared to normal T cells, potentially leading to ways to alter these pathways to improve outcomes for patients by increasing persistence. We will explore telomere-dependent senescence by overexpressing telomerase, the enzyme that lengthens telomeres, in CAR-T using an inducible system so we can turn on and off telomerase activity during repeated activation of the CAR-T cells. We will also examine telomerase activity at various time points from patients who have received CAR-T on a clinical trial. Telomere-independent senescence will be explored using a CRISPR screen. CRISPR is a novel technique that allows for targeted breaks in the DNA, which when left alone, results in loss of that gene, or a knockout. We will use this technique on senescent CAR-T, to identify gene knockouts that revert this, and identify targetable pathways to improve CAR-T persistence.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466532
Name
Sankaran Saambavi C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Improving the persistence of CAR T-cells by understanding senescence
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Car T-Cell; Cell Therapy; Chimeric Antigen Receptor; Crispr; Immunotherapy; Leukemia; Senescence; T Cell; Telomerase; Telomeres
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has led to improved survival for some patients with relapsed/refractory acute lymphoblastic leukemia (ALL). This therapy involves engineering T cells, a white blood cell, with a new gene, the CAR, so that it can recognize and kill the cancer cells. However, long-term survival remains short for many patients, with poor outcomes associated with a loss of the CAR-T cells. One possible reason for the loss of CAR-T cells is senescence, or aging, of the T cells, resulting in inactivity and cell death. Senescence can occur via telomere-dependent or independent pathways. Telomeres are repeats found on the ends of chromosomes that protect the cellular DNA from damage, and critical shortening of these leads to senescence. Telomere independent senescence is mediated by many different pathways. We propose to examine the pathways of senescence in CAR-T cells and how they differ compared to normal T cells, potentially leading to ways to alter these pathways to improve outcomes for patients by increasing persistence. We will explore telomere-dependent senescence by overexpressing telomerase, the enzyme that lengthens telomeres, in CAR-T using an inducible system so we can turn on and off telomerase activity during repeated activation of the CAR-T cells. We will also examine telomerase activity at various time points from patients who have received CAR-T on a clinical trial. Telomere-independent senescence will be explored using a CRISPR screen. CRISPR is a novel technique that allows for targeted breaks in the DNA, which when left alone, results in loss of that gene, or a knockout. We will use this technique on senescent CAR-T, to identify gene knockouts that revert this, and identify targetable pathways to improve CAR-T persistence.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sankaran, Saambavi C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~